What is the recommended management for polypoid nasal mucosal disease with active epistaxis?

Management of Polypoid Nasal Mucosal Disease with Active Epistaxis

For active epistaxis in the setting of polypoid nasal disease, immediately control bleeding using compressive therapy with topical vasoconstrictors (oxymetazoline or epinephrine 1:1,000), followed by directed cautery or nasal packing if needed, then address the underlying chronic rhinosinusitis with nasal polyposis (CRSwNP) with intranasal corticosteroids and consider biologics for refractory disease. 1, 2, 3

Acute Epistaxis Management

Initial Control Measures

• Apply direct compression as the first-line intervention for anterior bleeding, which accounts for >90% of epistaxis cases 3
• Use topical vasoconstrictors immediately: oxymetazoline nasal spray or cotton pledgets soaked in oxymetazoline or epinephrine 1:1,000 applied to the bleeding site stops 65-75% of nosebleeds 2, 3
• Consider tranexamic acid (topical or systemic) which achieves hemostasis in 78% of patients versus 35% with oxymetazoline alone 2

Escalation for Persistent Bleeding

• Perform directed cautery using silver nitrate on the decongested and anesthetized nasal mucosa if a specific bleeding source is identified—this is more effective than chemical cauterization with fewer recurrences (14.5% vs 35.1%) 2, 4
• Apply nasal packing if cautery fails: inflatable anterior nasal balloon packs (Rapid-Rhino) reliably control most anterior bleeds 4
• Use newer hemostatic materials such as hemostatic gauzes (Surgicel), thrombin matrix (Floseal), gelatin sponge (Spongostan), or fibrin glue—these are more effective with fewer complications than traditional packing 2

Posterior Epistaxis

• Add a Foley catheter nasopharyngeal balloon pack for posterior bleeding, which is more likely to require hospitalization and has twice the risk of needing packing compared to anterior epistaxis 3, 4
• Consider endoscopic cauterization or arterial ligation (primarily sphenopalatine artery) for refractory cases—endoscopic ligation is more effective than conventional packing (97% vs 62%), and cauterization is more effective than ligation 2
• Refer for interventional radiology embolization in intractable cases, which has an 80% success rate with comparable efficacy to surgical methods 2

Management of Underlying CRSwNP

Medical Therapy

• Initiate intranasal corticosteroids as the foundation of CRSwNP management with multiple delivery methods available 1, 5
• Consider biologics (dupilumab, omalizumab, or mepolizumab) for patients with refractory CRSwNP who have undergone or cannot undergo sinus surgery 1, 6
• Assess treatment response at 6 months; in poor responders, consider alternative biologics or revision surgery 6

Surgical Considerations

• Endoscopic sinus surgery remains a mainstay for CRSwNP, with newer techniques focused on improving access for topical steroid therapy 7
• Modified procedures such as Draf 3 (modified endoscopic Lothrop procedure) have demonstrated improved quality of life and decreased polyp recurrence 7

Critical Pitfalls to Avoid

• Do not perform bilateral simultaneous septal cautery due to risk of septal perforation 1
• Ensure adequate anesthesia and analgesia before any nasal manipulation to improve patient tolerance and procedural success 4
• Provide topical moisturizing therapy after acute management to facilitate mucosal healing 4
• Give patients oxymetazoline 0.05% nasal spray at discharge to address potential rebleeding 4

Follow-Up Strategy

• Monitor closely for biologic-related adverse events if biologics are initiated 6
• Reassess at regular intervals to determine if the polypoid disease is adequately controlled and whether epistaxis recurs 1